NASDAQ:BMRA

Biomerica - BMRA Stock Forecast, Price & News

$3.93

-0.05 (-1.26%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.64
▼
$4.01
50-Day Range: $2.64
▼
$3.98
52-Week Range: $2.56
▼
$7.38

Volume: 52,195 shs
Average Volume: 61,511 shs
Market Capitalization: $52.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.00

Biomerica MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 100.0% Downside
$0.00 Price Target
Short Interest: Healthy
2.90% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.95
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

411th out of 1,093 stocks

Diagnostic Substances Industry

9th out of 17 stocks

1.5

Analyst's Opinion

Consensus Rating
Biomerica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $0.00, Biomerica has a forecasted downside of 100.0% from its current price of $3.93.
Amount of Analyst Coverage
Biomerica has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.90% of the float of Biomerica has been sold short.
Short Interest Ratio / Days to Cover
Biomerica has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biomerica has recently decreased by 11.85%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Biomerica does not currently pay a dividend.
Dividend Growth
Biomerica does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BMRA.

3.3

News and Social Media Coverage

News Sentiment
Biomerica has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Biomerica this week, compared to 1 article on an average week.
Search Interest
2 people have searched for BMRA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Biomerica to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biomerica insiders have not sold or bought any company stock.
Percentage Held by Insiders
23.70% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 18.88% of the stock of Biomerica is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Biomerica is -10.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biomerica is -10.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Biomerica has a P/B Ratio of 6.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Biomerica (NASDAQ:BMRA) Stock

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

BMRA Stock News Headlines

September 30, 2022 | it.tmcnet.com

Biomerica's Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by Amazon

September 29, 2022 | benzinga.com

Thinking about buying stock in BigBear.ai, Bed Bath & Beyond, Atara Biotherapeutics, Stabilis Solutions, - Benzinga

September 29, 2022 | benzinga.com

Biomerica's Aware Breast Self Exam and EZ Detect Colon Disease Test Now Available On Amazon And Fulfilled - Benzinga

September 29, 2022 | finance.yahoo.com

Biomerica’s Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by Amazon

September 26, 2022 | globenewswire.com

Blood Testing Market to hit USD 123 Billion by 2030, says Global Market Insights Inc. - GlobeNewswire

September 14, 2022 | globenewswire.com

LifeMD Expands Primary Care Platform's Diagnostic - GlobeNewswire

September 9, 2022 | seekingalpha.com

Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now

September 5, 2022 | nasdaq.com

Biomerica (NASDAQ:BMRA) Is In A Strong Position To Grow Its Business - Nasdaq

September 2, 2022 | seekingalpha.com

Bright Minds, PaxMedica top healthcare gainers; PolyPid, Shuttle lead losers' pack - Seeking Alpha

August 31, 2022 | finance.yahoo.com

We're Interested To See How Biomerica (NASDAQ:BMRA) Uses Its Cash Hoard To Grow

August 30, 2022 | finance.yahoo.com

Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer - Yahoo Finance

August 30, 2022 | globenewswire.com

Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer - GlobeNewswire

August 30, 2022 | finance.yahoo.com

Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer

August 29, 2022 | finance.yahoo.com

Biomerica Reports Fiscal 2022 Year End Results - Yahoo Finance

August 29, 2022 | globenewswire.com

Biomerica Reports Fiscal 2022 Year End Results - GlobeNewswire

August 29, 2022 | finance.yahoo.com

Biomerica Reports Fiscal 2022 Year End Results

August 22, 2022 | reuters.com

BMRA.OQ - Biomerica Inc | Stock Price & Latest News | Reuters

August 16, 2022 | finance.yahoo.com

Global Blood Testing Market to Hoard around USD 140 billion in 2031, Market to Thrive with ~8% CAGR during 2022-2031; Rising Incidence of Infectious and Chronic Diseases Aid Growth- Kenneth Research - Yahoo Finance

August 16, 2022 | globenewswire.com

August 14, 2022 | seekingalpha.com

Biomerica (BMRA) Investor Presentation - Slideshow

August 12, 2022 | businesswire.com

Global Cardiac POC Testing Devices Market Report 2022: Rising Incidence, Mounting Economic and Social Burden of Cardiovascular Disease to Drive Growth - ResearchAndMarkets.com - Business Wire

July 14, 2022 | benzinga.com

Biomerica shares are trading higher after the company announced its Aware Breast Self Exam device will no - Benzinga

July 14, 2022 | nasdaq.com

Consumer Sector Update for 07/14/2022: CAG, ANGI, BMRA, WMT - Nasdaq

July 14, 2022 | benzinga.com

Dow Tumbles 450 Points; JPMorgan Shares Drop Following Earnings Miss - Benzinga

July 14, 2022 | benzinga.com

Why US Stocks Are Trading Lower Following Producer Inflation Data - Benzinga

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

BMRA Company Calendar

Last Earnings: 1/13/2022
Today: 10/01/2022
Next Earnings (Estimated): 10/13/2022
Fiscal Year End: 5/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BMRA
CUSIP: N/A
CIK: 73290
Web: www.biomerica.com
Phone: (949) 645-2111
Fax: 949-553-1231
Employees: 66
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $0.00
High Stock Price Forecast: $0.00
Low Stock Price Forecast: $10,000,000.00
Forecasted Upside/Downside: +230.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,530,000.00
Net Margins: -24.01%
Pretax Margin: -23.88%
Return on Equity: -50.64%
Return on Assets: -32.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.69
Quick Ratio: 3.49

Sales & Book Value

Annual Sales: $18.87 million
Price / Sales: 2.79
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.65 per share
Price / Book: 6.05

Miscellaneous

Outstanding Shares: 13,410,000
Free Float: 10,233,000
Market Cap: $52.70 million
Optionable: Not Optionable
Beta: -0.44

Key Executives

Mr. Zackary S. Irani (Age 56)
Chairman & CEO
Comp: $136.61k

Mr. Allen C. Barbieri (Age 64)
Exec. Vice-Chairman & Corp. Sec.
Comp: $90k

Mr. Steven Sloan (Age 52)
CFO & Treasurer
Comp: $166.67k

Ms. Lucy Liu Ph.D.
Director of Manufacturing & Technical Operations

Hans Boehringer
Sr. VP of POC R&D

Key Competitors

View All Competitors

Insiders & Institutions

Group One Trading L.P.
Sold 37,700 shares on 8/11/2022
Ownership: 0.093%

View All Insider Transactions
View All Institutional Transactions

BMRA Stock - Frequently Asked Questions

Should I buy or sell Biomerica stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BMRA shares.
View BMRA analyst ratings or view top-rated stocks.
What is Biomerica's stock price forecast for 2022?: 1 brokerages have issued twelve-month target prices for Biomerica's shares. Their BMRA share price forecasts range from $10,000,000.00 to $0.00. On average, they anticipate the company's stock price to reach $0.00 in the next year. This suggests that the stock has a possible downside of 100.0%.
View analysts price targets for BMRA or view top-rated stocks among Wall Street analysts.
How have BMRA shares performed in 2022?: Biomerica's stock was trading at $3.89 on January 1st, 2022. Since then, BMRA stock has increased by 1.0% and is now trading at $3.93.
View the best growth stocks for 2022 here.
When is Biomerica's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 13th 2022.
View our BMRA earnings forecast.

How were Biomerica's earnings last quarter?: Biomerica, Inc. (NASDAQ:BMRA) posted its quarterly earnings data on Thursday, January, 13th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. The company earned $4.65 million during the quarter. Biomerica had a negative net margin of 24.01% and a negative trailing twelve-month return on equity of 50.64%.
What other stocks do shareholders of Biomerica own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).
What is Biomerica's stock symbol?: Biomerica trades on the NASDAQ under the ticker symbol "BMRA."
How do I buy shares of Biomerica?: Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biomerica's stock price today?: One share of BMRA stock can currently be purchased for approximately $3.93.
How much money does Biomerica make?: Biomerica (NASDAQ:BMRA) has a market capitalization of $52.70 million and generates $18.87 million in revenue each year. The company earns $-4,530,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.
How can I contact Biomerica?: Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The official website for the company is www.biomerica.com. The company can be reached via phone at (949) 645-2111, via email at jnesbett@institutionalms.com, or via fax at 949-553-1231.

This page (NASDAQ:BMRA) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biomerica - BMRA Stock Forecast, Price & News

Biomerica MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Biomerica (NASDAQ:BMRA) Stock

BMRA Stock News Headlines

BMRA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BMRA Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™